News

Deal Announcements

ARMO Bio Raises Series B Venture Capital

Thursday, May 29, 2014 5:30:00 AM PDT | VentureDeal
   Redwood City, California  --  ARMO BioSciences has raised $30 million in its second round of institutional venture capital funding.

ARMO is developing immunotherapies for the treatment of cancer, cardiovascular diseases, fibrosis and inflammation.

NanoDmiension led the round, which included previous investors Kleiner Perkins Caufield & Byers, OrbiMed Advisors and DAG Ventures.

The company said it would use the funding proceeds to complete expansion cohorts of its Phase 1 study of AM0010.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1